241 related articles for article (PubMed ID: 23121546)
1. Oncogenic potential of cyclin kinase subunit-2 in cholangiocarcinoma.
Shen DY; Zhan YH; Wang QM; Rui G; Zhang ZM
Liver Int; 2013 Jan; 33(1):137-48. PubMed ID: 23121546
[TBL] [Abstract][Full Text] [Related]
2. Aberrant expression of Cks1 and Cks2 contributes to prostate tumorigenesis by promoting proliferation and inhibiting programmed cell death.
Lan Y; Zhang Y; Wang J; Lin C; Ittmann MM; Wang F
Int J Cancer; 2008 Aug; 123(3):543-51. PubMed ID: 18498131
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent kinase-associated proteins Cks1 and Cks2 are essential during early embryogenesis and for cell cycle progression in somatic cells.
Martinsson-Ahlzén HS; Liberal V; Grünenfelder B; Chaves SR; Spruck CH; Reed SI
Mol Cell Biol; 2008 Sep; 28(18):5698-709. PubMed ID: 18625720
[TBL] [Abstract][Full Text] [Related]
4. CKS2 promotes tumor progression and metastasis and is an independent predictor of poor prognosis in epithelial ovarian cancer.
Xu JH; Wang Y; Xu D
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3225-3234. PubMed ID: 31081074
[TBL] [Abstract][Full Text] [Related]
5. Microsomal prostaglandin E synthase-1 inhibits PTEN and promotes experimental cholangiocarcinogenesis and tumor progression.
Lu D; Han C; Wu T
Gastroenterology; 2011 Jun; 140(7):2084-94. PubMed ID: 21354147
[TBL] [Abstract][Full Text] [Related]
6. miR-26a and its target CKS2 modulate cell growth and tumorigenesis of papillary thyroid carcinoma.
Lv M; Zhang X; Li M; Chen Q; Ye M; Liang W; Ding L; Cai H; Fu D; Lv Z
PLoS One; 2013; 8(7):e67591. PubMed ID: 23861775
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor upregulates Skp2/Cks1 and p27(kip1) in human extrahepatic cholangiocarcinoma cells.
Kim JY; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Kim DH; Chae SW; Sohn JH
World J Gastroenterol; 2014 Jan; 20(3):755-73. PubMed ID: 24574749
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of CKS2 is associated with a poor prognosis and promotes cell proliferation and invasion in breast cancer.
Huang N; Wu Z; Hong H; Wang X; Yang F; Li H
Mol Med Rep; 2019 Jun; 19(6):4761-4769. PubMed ID: 30957190
[TBL] [Abstract][Full Text] [Related]
9. Aberrant expression of CKS2 induced by ELK1 contributes to malignant progression of pancreatic cancer.
Chen Q; Fu Y; Liu X; Wang P; Dai S; Zhu F; Liu T; Xu W; Wu J
Mol Carcinog; 2023 Dec; 62(12):1947-1959. PubMed ID: 37642304
[TBL] [Abstract][Full Text] [Related]
10. Cholangiocarcinoma cells express somatostatin receptor subtype 2 and respond to octreotide treatment.
Zhao B; Zhao H; Zhao N; Zhu XG
J Hepatobiliary Pancreat Surg; 2002; 9(4):497-502. PubMed ID: 12483273
[TBL] [Abstract][Full Text] [Related]
11. CKS2 Promotes the Growth in Non-Small-Cell Lung Cancer by Downregulating Cyclin-Dependent Kinase Inhibitor.
Wan Z; Wang L; Yang D; Li P; Liu Q; Wang B
Pathobiology; 2022; 89(1):13-22. PubMed ID: 34333494
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of overexpressed cyclin-dependent kinase subunits 1 and 2 in esophageal carcinoma.
Wang JJ; Fang ZX; Ye HM; You P; Cai MJ; Duan HB; Wang F; Zhang ZY
Dis Esophagus; 2013; 26(7):729-36. PubMed ID: 23301842
[TBL] [Abstract][Full Text] [Related]
13. CKS2 modulates cell-cycle progression of tongue squamous cell carcinoma cells partly via modulating the cellular distribution of DUTPase.
Gao F; Li C; Zhao X; Xie J; Fang G; Li Y
J Oral Pathol Med; 2021 Feb; 50(2):175-182. PubMed ID: 33107644
[TBL] [Abstract][Full Text] [Related]
14. Trefoil factors: tumor progression markers and mitogens via EGFR/MAPK activation in cholangiocarcinoma.
Kosriwong K; Menheniott TR; Giraud AS; Jearanaikoon P; Sripa B; Limpaiboon T
World J Gastroenterol; 2011 Mar; 17(12):1631-41. PubMed ID: 21472131
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
16. Clinical and biological impact of cyclin-dependent kinase subunit 2 in esophageal squamous cell carcinoma.
Kita Y; Nishizono Y; Okumura H; Uchikado Y; Sasaki K; Matsumoto M; Setoyama T; Tanoue K; Omoto I; Mori S; Owaki T; Ishigami S; Nakagawa H; Tanaka F; Mimori K; Mori M; Natsugoe S
Oncol Rep; 2014 May; 31(5):1986-92. PubMed ID: 24604089
[TBL] [Abstract][Full Text] [Related]
17. Expression of cyclin kinase subunit 2 in human breast cancer and its prognostic significance.
Wang J; Xu L; Liu Y; Chen J; Jiang H; Yang S; Tan H
Int J Clin Exp Pathol; 2014; 7(12):8593-601. PubMed ID: 25674223
[TBL] [Abstract][Full Text] [Related]
18. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.
Andersen JB; Spee B; Blechacz BR; Avital I; Komuta M; Barbour A; Conner EA; Gillen MC; Roskams T; Roberts LR; Factor VM; Thorgeirsson SS
Gastroenterology; 2012 Apr; 142(4):1021-1031.e15. PubMed ID: 22178589
[TBL] [Abstract][Full Text] [Related]
19. Cyclin-Dependent Kinase Regulatory Subunit 2 Indicated Poor Prognosis and Facilitated Aggressive Phenotype of Hepatocellular Carcinoma.
Zhang J; Song Q; Liu J; Lu L; Xu Y; Zheng W
Dis Markers; 2019; 2019():8964015. PubMed ID: 31781310
[TBL] [Abstract][Full Text] [Related]
20. EGFL7 promotes hepatocellular carcinoma cell proliferation and inhibits cell apoptosis through increasing CKS2 expression by activating Wnt/β-catenin signaling.
Li Z; Xue TQ; Yang C; Wang YL; Zhu XL; Ni CF
J Cell Biochem; 2018 Dec; 119(12):10327-10337. PubMed ID: 30129142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
